Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
32 0 |
Căutarea după subiecte similare conform CZU |
616-073.756.8 (2) |
Pathology. Clinical medicine (7211) |
SM ISO690:2012 ABASS, Alavi. Unparalleled contributions of FDG-PET imaging to medicine over the past 4 decades. In: Moldovan Medical Journal, 2018, nr. 61(S_RMI), p. 39. ISSN 2537-6373. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Moldovan Medical Journal | ||||||
Numărul 61(S_RMI) / 2018 / ISSN 2537-6373 /ISSNe 2537-6381 | ||||||
|
||||||
CZU: 616-073.756.8 | ||||||
Pag. 39-39 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background: Positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) is currently one of the most widely used imaging modalities. Both the technology and the radiopharmaceutical were conceived in the 1970s, facing a variety of challenges. Nowadays, a variety of PET techniques using partial volume correction and segmentation allow accurate quantification of metabolic activity in different tissues of the human body in normal and disease states. Content: The presentation reviews the long journey of FDG-PET from its origin up to date with a large number of case illustrations, including the first images obtained personally while working on developing the modality in the 1970’s. A brief summary of the imaging equipment and its evolution as well as the main contributions of FDG-PET imaging to medical practice and research activities are also discussed. Conclusion: FDG-PET-CT imaging has had a substantial impact on research and on the day to day practice of medicine. This has resulted in minimizing pain and suffering for millions of patients and in reducing the cost of health care worldwide. |
||||||
Cuvinte-cheie positron emission tomography, fluorodeoxyglucose, FDG-PET evolution |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-204049</cfResPublId> <cfResPublDate>2018-06-04</cfResPublDate> <cfVol>S_RMI</cfVol> <cfIssue>61</cfIssue> <cfStartPage>39</cfStartPage> <cfISSN>2537-6373</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/204049</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>Unparalleled contributions of FDG-PET imaging to medicine over the past 4 decades</cfTitle> <cfKeyw cfLangCode='EN' cfTrans='o'>positron emission tomography; fluorodeoxyglucose; FDG-PET evolution</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p>Background: Positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) is currently one of the most widely used imaging modalities. Both the technology and the radiopharmaceutical were conceived in the 1970s, facing a variety of challenges. Nowadays, a variety of PET techniques using partial volume correction and segmentation allow accurate quantification of metabolic activity in different tissues of the human body in normal and disease states. Content: The presentation reviews the long journey of FDG-PET from its origin up to date with a large number of case illustrations, including the first images obtained personally while working on developing the modality in the 1970’s. A brief summary of the imaging equipment and its evolution as well as the main contributions of FDG-PET imaging to medical practice and research activities are also discussed. Conclusion: FDG-PET-CT imaging has had a substantial impact on research and on the day to day practice of medicine. This has resulted in minimizing pain and suffering for millions of patients and in reducing the cost of health care worldwide.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2018-06-04T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2018-06-04T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-118504</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2018-06-04T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-118504</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-118504-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2018-06-04T24:00:00</cfStartDate> <cfFamilyNames>Abass</cfFamilyNames> <cfFirstNames>Alavi</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>